From: Sex effects on clinical features in LRRK2 G2385R carriers and non-carriers in Parkinson's disease
 | Male | Female | P-value (all G2385R carriers vs. all non-carriers) | |||||
---|---|---|---|---|---|---|---|---|
OR (95%CI) | p | Genetic power | OR (95%CI) | p | Genetic power | OR (95%CI) | p | |
EOPD | 0.430 (0.174–1.061) | 0.067 | 0.070 | 0.870 (0.355–2.130) | 0.760 | 0.007 | 0.595 (0.316–1.120) | 0.108 |
Advanced stage a | 0.487 (0.165–1.443) | 0.194 | 0.247 | 0.360 (0.102–1.273) | 0.113 | 0.177 | 0.425 (0.189–0.957) | 0.039 |
Impaired ADL a | 1.195 (0.557–2.563) | 0.647 | 0.074 | 1.228 (0.524- 2.877) | 0.637 | 0.078 | 1.167 (0.665–2.048) | 0.591 |
Motor dysfunction a | 1.540 (0.746–3.177) | 0.243 | 0.247 | 1.647 (0.739- 3.670) | 0.166 | 0.249 | 1.549 (0.908–2.642) | 0.108 |
Motor complication a | 1.779 (0.688- 4.600) | 0.234 | 0.391 | 1.372 (0.461–4.088) | 0.570 | 0.132 | 1.557 (0.763–3.180) | 0.224 |
Cognitive impairment b | 0.301 (0.135–0.668) | 0.003 | 0.005 | 0.709 (0.276–1.820) | 0.475 | 0.058 | 0.448 (0.248–0.809) | 0.008 |
Sleep disorder c | 0.857 (0.312–2.357) | 0.765 | 0.077 | 1.026 (0.385–2.739) | 0.959 | 0.048 | 1.084 (1.034–1.136) | 0.001 |
Mood disorder c | 0.781 (0.305–1.996) | 0.605 | 0.119 | 0.425 (0.140–1.284) | 0.129 | 0.169 | 0.587 (0.288–1.198) | 0.143 |
olfaction c | 0.605 (0.291–1.255) | 0.177 | 0.141 | 1.680 (0.702–4.020) | 0.244 | 0.299 | 0.976 (0.562–1.695) | 0.931 |
RBD c | 0.806 (0.386–1.685) | 0.567 | 0.102 | 1.123 (0.500–2.520) | 0.779 | 0.062 | 0.926 (0.539–1.592) | 0.781 |
Autonomic dysfunction c | 0.879 (0.439–1.762) | 0.717 | 0.070 | 0.401 (0.167–0.960) | 0.040 | 0.044 | 0.653 (0.387–1.102) | 0.110 |
EDS c | 0.804 (0.379–2.095) | 0.571 | 0.103 | 1.637 (0.695–3.854) | 0.259 | 1.637 | 1.070 (0.611–1.875) | 0.813 |
Life quality c | 1.050 (0.526–2.095) | 0.891 | 0.048 | 0.953 (0.437–2.080) | 0.903 | 0.953 | 1.001 (0.597–1.678) | 0.998 |
SN + c | 0.773 (0.236–2.530) | 0.670 | 0.125 | 1.602 (0.344–7.455) | 0.548 | 1.602 | 0.988 (0.388–2.519) | 0.980 |